Cellebrite DI (CLBT) Capital Expenditures (2020 - 2025)

Cellebrite DI (CLBT) has reported Capital Expenditures for 6 consecutive years, with -$4.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Capital Expenditures fell 24.48% year-over-year to -$4.0 million; the TTM figure through Dec 2025 stood at -$13.2 million (down 54.39% YoY), while the FY2025 annual figure was $13.2 million, up 54.39% from the prior year.
• Capital Expenditures came in at -$4.0 million for Q4 2025 at Cellebrite DI, down from -$3.3 million in the prior quarter.
• The five-year high for Capital Expenditures was $749000.0 in Q4 2021, with the low at -$4.0 million in Q4 2025.
• Average Capital Expenditures over 5 years is -$1.4 million, with a median of -$1.2 million recorded in 2022.
• Across the five-year window, Capital Expenditures jumped 1024.69% in 2021 and tumbled 1469.62% in 2023, its largest moves.
• Year by year, Capital Expenditures stood at $749000.0 in 2021, then tumbled by 285.71% to -$1.4 million in 2022, then plunged by 62.47% to -$2.3 million in 2023, then sank by 40.62% to -$3.2 million in 2024, then retreated by 24.48% to -$4.0 million in 2025.
• According to Business Quant data, Capital Expenditures over the past three periods registered -$4.0 million, -$3.3 million, and -$3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.